|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||131.43 / 176.85|
U.S. stocks climbed and the Dow Jones Industrial Average jumped more than 100 points thanks to gains in the tech and consumer sectors.
Stocks add to gains in a relief rally Tuesday following the the first of three presidential debates on Monday.
Amgen announced today (AMGN) that its Phase III trial for Kyprolis, a plasma cell cancer drug, produced results that were not statistically significant.
Stocks move higher in a relief rally Tuesday following the the first of three presidential debates on Monday.
Stock futures creep higher on Tuesday following the first of three presidential debates, though a drop in crude oil caps gains.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Amgen to Hold Analyst Call Today at 8:30 a.m. ET
Opportunity for Life Sciences and Biotech Startups to Submit Proposal to Win Golden Ticket
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
First Regulatory Approval for Company's Biosimilar Portfolio
The FDA approved Amgen's (AMGN) generic version of AbbVie's (ABBV) Humira drug.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.
First Study to Demonstrate That Lowering LDL Cholesterol With a PCSK9 Inhibitor Impacts Underlying Atherosclerotic Disease on top of Optimized Statin Therapy
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months
The once-mighty biotech has fallen, but entry opportunities will surface.
The FDA told Spectrum not to seek approval for its bladder cancer drug. Spectrum filed anyway but never told investors about the FDA warning.
Novel Treatment Administered Intravenously Would put Delivery of Important Therapy in the Hands of the Healthcare Provider
Significantly Greater Proportion of Patients on Erenumab Experienced a 50 Percent or More Reduction in Number of Migraine Days Compared to Placebo
Amgen's (AMGN) last run to highs stalled out, but the stock could still push through the old highs, according to TheStreet's Chris Versace and Bob Lang.
The shares have some power and legs to get up and through old highs.
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?